|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Wood DE, Akerley W, Bazhenova
LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA,
Demmy TL, et al: Non-small cell lung cancer, version 6.2015. J Natl
Compr Canc Netw. 13:515–524. 2015.PubMed/NCBI
|
|
3
|
Langer CJ, Besse B, Gualberto A, Brambilla
E and Soria JC: The evolving role of histology in the management of
advanced non-small-cell lung cancer. J Clin Oncol. 28:5311–5320.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davidson MR, Gazdar AF and Clarke BE: The
pivotal role of pathology in the management of lung cancer. J
Thorac Dis. 5:(Suppl 5). S463–S478. 2013.PubMed/NCBI
|
|
5
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network.
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lawrence MS, Stojanov P, Mermel CH,
Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander
ES and Getz G: Discovery and saturation analysis of cancer genes
across 21 tumour types. Nature. 505:495–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bellocq A, Antoine M, Flahault A, Philippe
C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L and
Cadranel J: Neutrophil alveolitis in bronchioloalveolar carcinoma:
Induction by tumor-derived interleukin-8 and relation to clinical
outcome. Am J Pathol. 152:83–92. 1998.PubMed/NCBI
|
|
11
|
Murdoch C, Muthana M, Coffelt SB and Lewis
CE: The role of myeloid cells in the promotion of tumour
angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Houghton AM, Rzymkiewicz DM, Ji H, Gregory
AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR,
et al: Neutrophil elastase-mediated degradation of IRS-1
accelerates lung tumor growth. Nat Med. 16:219–223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yarden Y, Kuang WJ, Yang-Feng T, Coussens
L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and
Ullrich A: Human proto-oncogene c-kit: A new cell surface receptor
tyrosine kinase for an unidentified ligand. EMBO J. 6:3341–3351.
1987.PubMed/NCBI
|
|
14
|
Hirota S: Gastrointestinal stromal tumors:
Their origin and cause. Int J Clin Oncol. 6:1–5. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Naeem M, Dahiya M, Clark JI, Creech SD and
Alkan S: Analysis of c-kit protein expression in small-cell lung
carcinoma and its implication for prognosis. Hum Pathol.
33:1182–1187. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Micke P, Basrai M, Faldum A, Bittinger F,
Rönnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R and
Hengstler JG: Characterization of c-kit expression in small cell
lung cancer: Prognostic and therapeutic implications. Clin Cancer
Res. 9:188–194. 2003.PubMed/NCBI
|
|
17
|
Krystal GW, Honsawek S, Litz J and
Buchdunger E: The selective tyrosine kinase inhibitor STI571
inhibits small cell lung cancer growth. Clin Cancer Res.
6:3319–3326. 2000.PubMed/NCBI
|
|
18
|
Wang WL, Healy ME, Sattler M, Verma S, Lin
J, Maulik G, Stiles CD, Griffin JD, Johnson BE and Salgia R: Growth
inhibition and modulation of kinase pathways of small cell lung
cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Oncogene. 19:3521–3528. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levina V, Marrangoni A, Wang T, Parikh S,
Su Y, Herberman R, Lokshin A and Gorelik E: Elimination of human
lung cancer stem cells through targeting of the stem cell
factor-c-kit autocrine signaling loop. Cancer Res. 70:338–346.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donnenberg AD, Zimmerlin L, Landreneau RJ,
Luketich JD and Donnenberg VS: KIT (CD117) expression in a subset
of non-small cell lung carcinoma (NSCLC) patients. PloS One.
7:e528852012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang F, Cao L, Sun Z, Jin J, Fang H, Zhang
W and Guan X: Evaluation of breast cancer stem cells and intratumor
stemness heterogeneity in triple-negative breast cancer as
prognostic factors. Int J Biol Sci. 12:1568–1577. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song W, Li H, Tao K, Li R, Song Z, Zhao Q,
Zhang F and Dou K: Expression and clinical significance of the stem
cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract.
62:1212–1218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hassan HT: c-Kit expression in human
normal and malignant stem cells prognostic and therapeutic
implications. Leuk Res. 33:5–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alamgeer M, Peacock CD, Matsui W, Ganju V
and Watkins DN: Cancer stem cells in lung cancer: Evidence and
controversies. Respirology. 18:757–764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelsey CR, Marks LB, Hollis D, Hubbs JL,
Ready NE, D'Amico TA and Boyd JA: Local recurrence after surgery
for early stage lung cancer: An 11-year experience with 975
patients. Cancer. 115:5218–5227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ooi AT, Mah V, Nickerson DW, Gilbert JL,
Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, et al:
Presence of a putative tumor-initiating progenitor cell population
predicts poor prognosis in smokers with non-small cell lung cancer.
Cancer Res. 70:6639–6648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S,
et al: Highly tumorigenic lung cancer CD133+ cells display
stem-like features and are spared by cisplatin treatment. Proc Natl
Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Salnikov AV, Gladkich J, Moldenhauer G,
Volm M, Mattern J and Herr I: CD133 is indicative for a resistance
phenotype but does not represent a prognostic marker for survival
of non-small cell lung cancer patients. Int J Cancer. 126:950–958.
2010.PubMed/NCBI
|
|
30
|
Cui F, Wang J, Chen D and Chen YJ: CD133
is a temporary marker of cancer stem cells in small cell lung
cancer, but not in non-small cell lung cancer. Oncol Rep.
25:701–708. 2011.PubMed/NCBI
|
